Conference Call and Webcast. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the Fulcrum’s website at wxx.xxxxxxxxx.xxx or by clicking here. Following the live webcast, an archived replay will also be available. About Losmapimod Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum’s discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Results reported from the Phase 2 ReDUX4 trial demonstrated a slowing of disease progression and improved function, including positive impacts on upper extremity strength and functional measures supporting losmapimod’s potential to be a transformative therapy for the treatment of FSHD. Although losmapimod had never previously been explored in muscular dystrophies, it had been evaluated in more than 3,600 subjects in clinical trials across multiple other indications, with no safety signals attributed to losmapimod. Losmapimod has been granted U.S. Food and Drug Administration (FDA) Fast Track designation and Orphan Drug Designation for the treatment of FSHD. Losmapimod is currently being evaluated in a Phase 3 multi-center randomized, double-blind, placebo-controlled, 48-week parallel-group study in people with FSHD (NCT05397470). About FSHD FSHD is a serious, rare, progressive and debilitating disease for which there are no approved treatments. It is characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving primarily the face, scapula and shoulders, upper arms, and abdomen. Impact on patients includes profound decreases in the ability to perform activities of daily living, loss of upper limb function, loss of mobility and independence and chronic pain. FSHD is one of the most common forms of muscular dystrophy and has an estimated patient population of 30,000 in the United States alone. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatme...
Conference Call and Webcast. Amicus Therapeutics will host a conference call and webcast today, July 17, 2012 at 5:00 P.M. ET to discuss the expanded agreement with GSK and provide additional details surrounding the new chaperone-ERT co-formulation. Interested participants and investors may access the live conference call by dialing 000-000-0000 (U.S./Canada) or 000-000-0000 (international). An audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at xxxx://xxx.xxxxxxxxxxxxxxxxxx.xxx, and will be archived for 30 days. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. A telephonic replay of the call will be available for seven days beginning at 8 p.m. ET today. Access numbers for this replay are 000-000-0000 (U.S./Canada) and 000-000-0000 (international); participant code 11288561.
Conference Call and Webcast. Equinox Gold and Leagold will hold a joint conference call and webcast on December 16, 2019 at 7am PT/10am ET to discuss the Transaction. Participants may dial in using the numbers below (no access code is needed). Toll free Canada/US: 0-000-000-0000 International: +0-000-000-0000 Login to the webcast The conference call will be available for playback until January 16, 2020 by dialing 0-000-000-0000 (toll free Canada/US) or +0-000-000-0000 (international) and quoting access code 3947. The webcast will be archived on both the Equinox Gold and Leagold websites until the Transaction closes. About Equinox Gold Equinox Gold is a Canadian mining company with a multi-million-ounce gold reserve base and growth potential from three wholly owned gold mines. The Company is producing gold from its Mesquite gold mine in California and its Aurizona gold mine in Brazil and is constructing its Castle Mountain gold mine in California with the target of pouring gold in Q3 2020. Equinox Gold is listed on the TSX and the NYSE American under the trading symbol EQX. Further information about Equinox Gold's portfolio of assets and long-term growth strategy is available at xxx.xxxxxxxxxxx.xxx.
Conference Call and Webcast. Starwood will conduct a conference call and webcast for the investment community today at 9:00 a.m. ET to discuss today’s announcement. To participate, please dial (000) 000-0000 (within U.S.) or (000) 000-0000 (outside U.S.) 15 minutes prior to the start of the call and enter conference ID number 82311682. A playback of the conference call will be available through April 16, 2007. To access the playback, please dial (000) 000-0000 (within U.S.) or (000) 000-0000 (outside U.S.) and enter conference ID number 82311682. The conference call will be available through simultaneous webcast in the Investor Relations/Press Releases section of the Company’s website at .
Conference Call and Webcast. Medgenics will host a conference call and live audio webcast on Monday, June 6, 2016 at 11:00 a.m. EDT to discuss the transaction. In order to participate in the conference call, please dial (000) 000-0000 (domestic) or (000) 000-0000 (international). The conference ID number is 2641940. The live webcast can be accessed under “Events” in the Investors section of the Company’s website at wxx.xxxxxxxxx.xxx or you may use the link: hxxxx://xxx.xxxxxxxxx0.xxx/Xxxxxxx/Page/1395/15455 A replay of the call will be available two hours after the end of the conference on June 6, 2016 through August 9, 2016. To access the replay, please dial 800-000-0000 (domestic) or 719-457-0820 (international) and reference the conference ID number: 2641940. The archived webcast will be available for 90 days in the Investor section of Medgenics’ website at wxx.xxxxxxxxx.xxx. About Severe Pediatric Onset Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD) is a disease that causes chronic relapsing inflammation of the intestines. There are two major types of IBD; Ulcerative Colitis which affects the colon, and Crohn’s Disease which effects the entire GI tract. Both diseases are treated with a variety of anti-inflammatory drugs, including steroids, antibiotics, and biologics. Disease etiology is not well understood, but it is believed that both genetics and environmental factors play a major role at various stages and ages of disease onset. IBD affects people of all ages with approximately 2.0 million people affected by the disease in the United States and Europe. The pediatric form of the disease is less common but frequently more severe, affecting more than 50,000 children in the USA. The incidence appears to be increasing. The disease in children is often more aggressive than in adults, more frequently leading to complications, hospitalization, surgery and even death. In children, IBD can also impact physical and emotional growth, interfere with school and social development. About the anti-LIGHT Monoclonal Antibody The anti-LIGHT monoclonal antibody is a Phase 2-ready first in class human monoclonal antibody offering a novel molecular approach to treating IBD and potentially other autoimmune diseases. The anti-LIGHT monoclonal antibody binds the pro-inflammatory cytokine, LIGHT (ligand for herpesvirus entry mediator), which is believed to be a major contributor to the chronic relapsing inflammation of IBD and other autoimmune diseases. Normally LIGHT is bound to, and down...
Conference Call and Webcast. Management will host a live conference call and audio webcast later today to discuss the highlights of the Transaction as follows: Date & Time: Thursday, January 13, 2022 at 1:00 p.m. PT / 4:00 p.m. ET Telephone: Toll-free in Canada and the US +0-000-000-0000 Local or International +0-000-000-0000 Please allow 10 minutes to be connected to the conference call.
